Compare BOC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | LCTX |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 388.6M |
| IPO Year | 2010 | 1996 |
| Metric | BOC | LCTX |
|---|---|---|
| Price | $13.30 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 271.2K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $114,376,348.00 | $14,556,000.00 |
| Revenue This Year | $5.79 | $109.40 |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.64 | ★ 53.24 |
| 52 Week Low | $10.52 | $0.65 |
| 52 Week High | $14.50 | $2.09 |
| Indicator | BOC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 34.20 |
| Support Level | $11.95 | $1.14 |
| Resistance Level | $13.93 | $1.31 |
| Average True Range (ATR) | 0.55 | 0.07 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 83.69 | 5.71 |
Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.